Oxytocin's Effects on Face Attentional Processing

Healthy Clinical Trial

Official title:

The Modulatory Effect of Oxytocin on Attentional Processing of Emotional Faces

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04413786
• Other study ID #: UESTC-neuSCAN-71
• Status: Completed
• Phase: N/A
• Start date: October 14, 2019
• Est. completion date: December 26, 2021

Study information

• Verified date: February 2022
• Source: University of Electronic Science and Technology of China
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To investigate whether intranasal oxytocin (24IU) treatment has a regulatory effect on attentional processing of emotional faces.

Description:

In a placebo-controlled double-blind between-subject design experiment, investigators plan to investigate the effect of oxytocin treatment on attentional processing of emotional faces. Subjects complete questionnaires in Chinese versions before treatment administration, including the Beck Depression Inventory, Autism Spectrum Quotient , Trait Anxiety Inventory, Toronto Alexithymia Scale, Multidimentional Assessment of Interoceptive Awareness. This experiment consists of two tasks including Emotional Face Cue-target Task and Visual Search Task. In the first task, subjects need to make a response to judge the position of target after a cue-target is presented. In the second task, subjects are asked to search the target "U" or inverted "U" placed on the nose of emotional/neutral faces and make an choices based on their oorientation. During these phases, subjects' response accuracy, response time and electrophysiological activity (ERP) are recorded.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: December 26, 2021
• Est. primary completion date: December 16, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• Healthy subjects without past or current psychiatric or neurological disorders.

Exclusion Criteria:

• history of head injury

• medical or psychiatric illness

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• oxytocin treatment
intranasal administration of oxytocin (24IU)
• placebo treatment
intranasal administration of placebo (24IU)

Locations

Country	Name	City	State
China	School of life science and technology, University of Electronic Science and Technology of China	Chengdu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
University of Electronic Science and Technology of China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response time in reponse to different emotional face targets.	Response time in discriminating which side (left or right) the emotional face target appear.	1 hour
Primary	N2pc	N2pc is an enhanced negative event-related potential typically elicited at posterior electrodes (e.g., PO7 and PO8) contralateral to the target presented among distractors between 180 and 300 ms after the onset of stimuli.; display.	1 hour
Secondary	Response accuracy in response to different emotional face targets.	Response accuracy is caculated by the precentage of correct responses among the total responses in discriminating the position (left or right side) of different face conditions.	1 hour